The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats

[21] Snigdha S(1991) receptors in the phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats Am J Psychiatry 148 1301-1308

[22] Shahid M(2002)5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release World J Biol Psychiatry 3 133-146

[23] Neill JC(2007)Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism Arch Gen Psychiatry 64 633-647

[24] Tarazi FI(1991)Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity J Neuropsychiatry Clin Neurosci 3 269-275

[25] Coyle JT(1999)Recent advances in the phencyclidine model of schizophrenia Harv Rev Psychiatry 7 125-143

[26] Depoortère R(1999)Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder—implications for psychopharmacology J Pharmacol Exp Ther 288 774-781

[27] Auclair AL(1995)Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Neuropsychopharmacology 13 9-19

[28] Bardin L(2001)Attention and higher cortical functions in schizophrenia Neuropsychopharmacology 25 455-467

[29] Bruins Slot L(2005)NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders Psychopharmacology (Berl) 183 144-153

[30] Kleven MS(2010)Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens Br J Pharmacol 160 1929-1940

[21] Snigdha S(1991) receptors in the phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats Am J Psychiatry 148 1301-1308

[22] Shahid M(2002)5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release World J Biol Psychiatry 3 133-146

[23] Neill JC(2007)Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism Arch Gen Psychiatry 64 633-647

[24] Tarazi FI(1991)Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity J Neuropsychiatry Clin Neurosci 3 269-275

[25] Coyle JT(1999)Recent advances in the phencyclidine model of schizophrenia Harv Rev Psychiatry 7 125-143

[26] Depoortère R(1999)Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder—implications for psychopharmacology J Pharmacol Exp Ther 288 774-781

[27] Auclair AL(1995)Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Neuropsychopharmacology 13 9-19

[28] Bardin L(2001)Attention and higher cortical functions in schizophrenia Neuropsychopharmacology 25 455-467

[29] Bruins Slot L(2005)NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders Psychopharmacology (Berl) 183 144-153

[30] Kleven MS(2010)Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens Br J Pharmacol 160 1929-1940